Genetics of polycystic ovary syndrome

Hippokratia

Volumn 13, Issue 4, 2009, Pages 216-223

  Prapas, N ^a   Karkanaki, A ^a,b   Prapas, I ^a   Kalogiannidis, I ^a   Katsikis, I ^a   Panidis, D ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b NONE   (Greece)

Author keywords

Etiology of PCOS genetics of PCOS; Polycystic ovary syndrome

Indexed keywords

CALPAIN 10; GONADOTROPIN; INSULIN; INSULIN RECEPTOR; STEROID;

CHRONIC INFLAMMATION; GENE; GENETIC ANALYSIS; HORMONE ACTION; HUMAN; HYPERANDROGENISM; INSULIN RELEASE; OVARY POLYCYSTIC DISEASE; REVIEW; STEROIDOGENESIS;

EID: 70350180754     PISSN: 11084189     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (126)

1. Cooper HE, Spellacy WN, Prem KA, Cohen WD. Hereditary factors in the Stein-Leventhal syndrome. Am J Obstet Gynecol. 1968; 100: 371-387.
2. Amato P and Simpson JL. The genetics of polycystic ovary syndrome. Best Pract Res Clin Obstet Gynaecol. 2005; 18: 707-718.
3. Wilroy RS Jr, Givens JR, Wiser WL, Coleman SA, Andersen RN, Summitt RL. Hyperthecosis: an inheritable formof polycystic ovarian disease. Birth Defects:Original Article Series. 1975; 11: 81-85.
4. Givens JR. Familial polycystic ovarian disease. Endocrinol Metab Clin N Am. 1988; 17: 771-783.
5. Franks S, Gharani N, Waterworth D, et al. The genetic basis of polycystic ovary syndrome. Hum Reprod. 1997; 12:2641-2648. (Pubitemid 28031723)
6. Jahanfar S, Eden JA. Genetic and non-genetic theories on the etiology of polycystic ovary syndrome. Gynecol Endocrinol. 1996; 10: 357-364. (Pubitemid 26364676)
7. Unluturk U, Harmanci A, Kocaefe C, Yildiz BO. The genetic basis of the polycystic ovary syndrome: a literature review including discussion of PPAR-γ. PPAR Res. 2007;1-23. (Pubitemid 46415047)
8. Franks S, Gilling-Smith C, Gharani N, McCarthy M. Pathogenesis of polycystic ovary syndrome: evidence for a genetically determined disorder of ovarian androgen production. Hum Fertil. 2000; 3: 77-79. (Pubitemid 30678864)
9. Gharani N, Waterworth DM, Batty S, et al. Association of the steroid synthesis gene CYP11a with polycystic ovary syndrome and hyperandrogenism. Hum Mol Gen. 1997; 6: 397-402. (Pubitemid 27116459)
10. Diamanti-Kandarakis E, BartzisMI, Bergiele AT, Tsianateli TC, Kouli CR. Microsatellite polymorphism (tttta)n at -528 base pairs of gene CYP11α influences hyperandrogenemia in patients with polycystic ovary syndrome. Fertil Steril. 2000; 4: 735-741. (Pubitemid 30154112)
11. Wang Y, Wu XK, Cao YX, et al. Microsatellite polymorphism of (tttta)n in the promoter of CYP11a gene in Chinese women with polycystic ovary syndrome," Zhonghua Yi Xue Za Zhi. 2005; 85: 3396-3400.
12. Gaasenbeek M, Powell BL, Sovio U, et al. Large-scale analysis of the relationship between CYP11A promoter variation, polycystic ovarian syndrome, and serum testosterone. J Clinl Endocrino Metab. 2004; 89: 2408-2413. (Pubitemid 38619883)
13. Tan L, Zhu G. Relationship between the microsatellite polymorphism of CYP11α gene and the pathogenesis of hyperan-drogenism of polycystic ovary syndrome in Chinese. Chin J Med Gen 2005; 22: 216-218. (Pubitemid 40529722)
14. Escobar-Morreale H, Pazos F, Potau N, Garcia-Robles R, Sancho JM, Varela C. Ovarian suppression with triptorelin and adrenal stimulation with adrenocorticotropin in functional hyperadrogenism: role of adrenal and ovarian cytochrome P450c17α. Fertil Steri. 1994; 62: 521-530. (Pubitemid 24273200)
15. Azziz R, Bradley EL Jr, Potter HD, Boots LR. Adrenal androgen excess in women: lack of a role for 17-hydroxylase and 17,20-lyase dysregulation. J Clin Endocrinol Metab. 1995; 80: 400-405.
16. Witchel SF, Aston CE.The role of heterozygosity for CYP21 in the polycystic ovary syndrome. J Pediatr Endocrinol Metab. 2000; 13 (Suppl 5): 1315-1317.
17. Witchel SF, Lee PA, Suda-Hartman M,.Hoffman EP. Hyperan-drogenism and manifesting heterozygotes for 21-hydroxylase deficiency. Biochem Mol Med. 1997; 62: 151-158.
18. Escobar-Morreale HF, San Millan JL, Smith RR, Sancho J, Witchel SF. The presence of the 21-hydroxylase deficiency carrier status in hirsute women: phenotypegenotype correlations. Fertil Steril. 1999; 72: 629-638. (Pubitemid 29475120)
19. Glintborg D, Hermann AP, Brusgaard K, Hangaard J, Hagen C, Andersen M. Significantly higher adrenocorticotropin-stimulated cortisol and 17-hydroxyprogesterone levels in 337 consecutive, premenopausal, caucasian, hirsute patients compared with healthy controls. J Clil Endocrinol Metab. 2005; 90: 1347-1353. (Pubitemid 40463986)
20. Picado-Leonard J, Miller WL. Cloning and sequence of the human gene for P450c17 (steroid 17α-hydroxylase/ 17,20lyase): similarity with the gene for P450c21. DNA. 1987; 6: 439-448. (Pubitemid 18085844)
21. Escobar-Morreale HF, Serrano-Gotarredona J, Garcýa-Robles R, Sancho JM, Varela C. Lack of an ovarian function influence on the increased adrenal androgen secretion present in women with functional ovarian hyperandrogenism. Fertil Steril. 1997; 67: 654-662. (Pubitemid 27157720)
22. Wickenheisser JK, Quinn PG, Nelson VL, Legro RS, Strauss JF III, McAllister LM. Differential activity of the cytochrome P450 17α- hydroxylase and steroidogenic acute regulatory protein gene promoters in normal and polycystic ovary syndrome theca cells. J Clin Endocrinol Metab. 2000; 85: 2304-2311.
23. Wickenheisser JK, Nelson-Degrave VL, Quinn PJ, McAllister JM. Increased cytochrorne P450 17α-hydroxylase promoter function in theca cells isolated from patients with polycystic ovary syndrome involves nuclear factor-1. Mol Endocrinol. 2004; 18: 588-605.
24. Wickenheisser JK, Nelson-DeGrave VL, McAllister JM. Dys-regulation of cytochrome P450 17α-hydroxylase messenger ribonucleic acid stability in theca cells isolated from women with polycystic ovary syndrome. J Clin Endocrinol Metabol. 2005; 90: 1720-1727. (Pubitemid 40464044)
25. Carey AH, Waterworth D, Patel K, et al. Polycystic ovaries and premature male pattern baldness are associated with one allele of the steroid metabolism gene CYP17. Hum Mol Gen. 1994; 3: 1873-1876. (Pubitemid 24310487)
26. Gharani N, Waterworth DM, Williamson R, Franks S. 5'polymorphism of the CYP17 gene is not associated with serum testosterone levels in women with polycystic ovaries. J Clin Endocrinol Metab. 1996; 81: 4174. (Pubitemid 26380437)
27. Techatraisak K, Conway GS, Rumsby G. Frequency of a polymorphism in the regulatory region of the 17α-hydroxylase- 17,20-lyase (CYP17) gene in hyperandrogenic states. Clin Endocrinol. 1997; 46: 131-134. (Pubitemid 27122156)
28. Witchel SF, Lee PA, Suda-Hartman M, Smith R, Hoffman EP. 17α-hydroxylase/17,20-lyase dysregulation is not caused by mutations in the coding regions of CYP17. J Pediatr Adol Gynecol. 1998; 11: 133-137. (Pubitemid 28429948)
29. Kahsar-Miller M, Boots LR, Bartolucci A, Azziz R. Role of a CYP17 polymorphism in the regulation of circulating dehydroepiandrosterone sulfate levels in women with polycystic ovary syndrome. Fertil Steril. 2004; 82: 973-975. (Pubitemid 39346456)
30. Simpson ER, Mahendroo MS, Means GD, et al. Aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. Endocrine Rev. 1994; 15: 342-355.
31. Chen S, Besman MJ, Sparkes RS, et al. Human aromatase: cDNA cloning, Southern blot analysis, and assignment of the gene to chromosome 15. DNA. 1988; 7: 27-38.
32. Harada N, Ogawa H, Shozu M, Yamada K. Genetic studies to characterize the origin of the mutation in placental aromatase deficiency. Am J Hum Gen. 1992; 51: 666-672.
33. Ito Y, Fisher CR, Conte FA, Grumbach MM, Simpson ER. Molecular basis of aromatase deficiency in an adult female with sexual infantilism and polycystic ovaries. Proceedings of the National Academy of Sciences of the United States of America. 1993; 90: 11673-11677. (Pubitemid 24008701)
34. Erickson GF, Hsueh AJW, Quigley ME, Rebar RW, Yen SS. Functional studies of aromatase activity in human granulosa cells from normal and polycystic ovaries. J Clin Endocrinol Metab. 1979; 49: 514-519.
35. Jakimiuk AJ, Weitsman SR, Brzechffa PR, Magoffin DA. Aromatase mRNA expression in individual follicles from polycystic ovaries. MolHum Reprod. 1998; 4: 1-8.
36. Petry CJ, Ong KK, Michelmore KF, et al. Association of aromatase (CYP 19) gene variation with features of hyperan-drogenism in two populations of young women. Hum Reprod. 2005; 20: 1837-1843.
37. Petry CJ, Ong KK, Michelmore KF, et al. Associations between common variation in the aromatase gene promoter region and testosterone concentrations in two young female populations. J Ster Biochem Mo Biol. 2006; 98: 199-206.
38. Lubahn DB, Joseph DR, Sullivan PM, Willard HF, French FS, Wilson EM. Cloning of human androgen receptor complementary DNA and localization to the X chromomose. Science. 1988; 240: 327-330. (Pubitemid 18116696)
39. Carson-Jurica MA, Schrader WT, O'Malley BW. Steroid receptor family: structure and functions. Endocrine Rev. 1990; 11: 201-220.
40. Chamberlain NL, Driver ED, Miesfeld RL. The length and location of CAG trinucleotide repeats in the androgen receptor N-terminal domain affect transactivation function. Nucleic Acids Res. 1994; 22: 3181-3186.
41. Giovannucci E, Stampfer MJ, Krithivas K, et al. The CAG repeat within the androgen receptor gene and its relationship to prostate cancer. Proceedings of the National Academy of Sciences of the United States of America. 1997; 94: 3320-3323. (Pubitemid 27157309)
42. Tut TG, Ghadessy FJ, Trifiro MA, Pinsky L, Yong LE. Long polyglutamine tracts in the androgen receptor are associated with reduced trans-activation, impaired sperm production, and male infertility. J Clin Endocrinol Metab. 1997; 82: 3777-3782. (Pubitemid 27509371)
43. Dowsing AT, Yong EL, Clark M, McLachlan RI, De Kretser DM, Trounson AO. Linkage between male infertility and trinucleotide repeat expansion in the androgenreceptor gene. Lancet. 1999; 354: 640-643. (Pubitemid 29391429)
44. Mifsud A, Ramirez S, Yong EL. Androgen receptor gene CAG trinucleotide repeats in anovulatory infertility and polycystic ovaries. J Clin Endocrinol Metab. 2000; 85: 3484-3488. (Pubitemid 30944569)
45. Urbanek M, Legro RS, Driscoll DA, et al. Thirty-seven candidate genes for polycystic ovary syndrome: strongest evidence for linkage is with follistatin. Proceedings of the National Academy of Sciences of the United States of America. 1999; 96: 8573-8578. (Pubitemid 29354833)
46. Hickey T, Chandy A, Norman RJ. The androgen receptor CAG repeat polymorphism and X-chromosome inactivation in Australian Caucasian women with infertility related to polycystic ovary syndrome. J Clin Endocrinol Metab. 2002; 87: 161-165. (Pubitemid 34084686)
47. Pugeat M, Crave JC, Tourniaire J, Forest MG. Clinical utility of sex hormone-binding globulin measurement. Horm Res 1996; 45: 148-155. (Pubitemid 26079699)
48. Selby C. Sex hormone binding globulin: origin, function and clinical significance. An Clin Biochem. 1990; 27: 532-541. (Pubitemid 20377170)
49. Berube D, Seralini GE, Gagne R, Hammond GL. Localization of the human sex hormone-binding globulin gene (SHBG) to the short arm of chromosome 17 (17p12→p13). Cytogenet Cell Genet. 1990; 54: 65-67.
50. Hogeveen KN, Talikka M, Hammond GL. Human sex hormone- binding globulin promoter activity is influenced by a (TAAAA)n repeat element within an Alu sequence. J Biol Chem. 2001; 276: 36383-36390. (Pubitemid 37390813)
51. Xita N, Tsatsoulis A, Chatzikyriakidou A, Georgiou I. Association of the (TAAAA)n repeat polymorphism in the sex hormone-binding globulin (SHBG) gene with polycystic ovary syndrome and relation to SHBG serum levels. J Clin Endocrinol Metab. 2003; 88: 5976-5980. (Pubitemid 38033081)
52. Cousin P, Calemard-Michel L, Lejeune H, et al. Influence of SHBG gene pentanucleotide TAAAA repeat and D327N polymorphism on serum sex hormone-binding globulin concentration in hirsute women. J Clin Endocrinol Metab. 2004; 89: 917-924. (Pubitemid 38269911)
53. Furui K, Suganuma N, Tsukahara SI, et al. Identification of two point mutations in the gene coding luteinising hormone (LH) β-subunit, associated with immunologically anomalous LH variants. J Clin Endocrinol Metab. 1994; 78: 107-113. (Pubitemid 24026757)
54. Okuda K, Yamada T, Imoto H, Komatsubara H, Sugimoto O. Antigenic alteration of an anomalous human luteinizing hormone caused by two chorionic gonadotropin type amino-acid substitutions. Biochem Biophys Res Communic. 1994; 200: 584-590. (Pubitemid 24183647)
55. Haavisto AM, Pettersson K, Bergendahl M, Virkamaki A, Huhtaniemi I. Occurrence and biological properties of a common genetic variant of luteinizing hormone. J Clin Endocrinol Metab. 1995; 80: 1257-1263.
56. Rajkhowa M, Talbot JA, Jones PW, et al. Prevalence of an immunological LH β-subunit variant in a UK population of healthy women and women with polycystic ovary syndrome. Clin Endocrinol. 1995; 43: 297-303.
57. Nilsson C, Pettersson K, Millar RP, Coerver KA, Matzuk MM, Huhtaniemi IT. Worldwide frequency of a common genetic variant of luteinizing hormone: an international collaborative research. Fertil Steril. 1997; 67: 998-1004. (Pubitemid 27241889)
58. Ramanujam LN, Liao WX, Roy AC, Loganath A, Goh HH, Ng SC. Association of molecular variants of luteinizing hormone with menstrual disorders. Clin Endocrinol. 1999; 51: 243-246. (Pubitemid 29378911)
59. Elter K, Erel CT, Cine N, Ozbek U, Hacihanefioglu B, Ertungealp E. Role of the mutations Trp8 → Arg and Ile15→ Thr of the human luteinizing hormone β-subunit in women with polycystic ovary syndrome. Fertil Steril. 1999; 71: 425-430. (Pubitemid 29094116)
60. Knight PG, Glister C. Potential local regulatory functions of inhibins, activins and follistatin in the ovary. Reprod. 2001; 121: 503-512. (Pubitemid 32327912)
61. Guo Q, Kumar TR, Woodruff T, Hadsell LA, De-Mayo FJ, Matzuk MM. Overexpression of mouse follistatin causes reproductive defects in transgenic mice. Mol Endocrinol. 1998; 12: 96-106. (Pubitemid 28124783)
62. Legro RS, Spielman R, Urbanek M, Driscoll D, Strauss JF III, Dunaif A. Phenotype and genotype in polycystic ovary syndrome. Recent Prog Horm Res. 1998; 53: 217-256. (Pubitemid 128472743)
63. Urbanek M, Wu X, Vickery KR, et al. Allelic variants of the follistatin gene in polycystic ovary syndrome. J Clin Endocrinol Metab. 2000; 85: 4455-4461. (Pubitemid 32157618)
64. Calvo RM, Villuendas G, Sancho J, San Millan JL, Escobar- Morreale HF. Role of the follistatin gene in women with polycystic ovary syndrome. Fertil Steril. 2001; 75: 1020-1023. (Pubitemid 32401685)
65. Junien C, van Heyningen V. Report of the committee on the genetic constitution of chromosome 11. Cytogenet Cell Genet. 1990; 55: 153-169.
66. Kennedy GC, German MS, Rutter WJ. The minisatellite in the diabetes susceptibility locus IDDM2 regulates insulin transcription. Nat Genet. 1995; 9: 293-298.
67. Paquette J, Giannoukakis N, Polychronakos C, Vafiadis P, Deal C. The INS 5′ variable number of tandem repeats is associated with IGF2 expression in humans. J Biol Chem. 1998; 273: 14158-14164. (Pubitemid 28319124)
68. Bell GI, Selby MJ, Rutter WJ. The highly polymorphic region near the human insulin gene is composed of simple tandemly repeating sequences. Nature. 1982; 295: 31-35.
69. Weaver JU, Kopelman PG, Hitman GA. Central obesity and hyperinsulinaemia in women are associated with polymorphism in the 5' flanking region of the human insulin gene. Eur J Clin Invest. 1992; 22: 265-270.
70. Ong KKL, Phillips DI, Fall C, et al. The insulin gene VNTR, type 2 diabetes and birth weight. Nat Genet. 1999; 21: 262-263. (Pubitemid 29124930)
71. Dunaif A, Segal KR, Futterweit W, Dobrjansky A. Profound peripheral insulin resistance, independent of obesity, in polycystic ovary syndrome. Diabetes. 1989; 38: 1165-1174. (Pubitemid 19250404)
72. Dunaif A, Segal KR, Shelley DR, Green G, Dobrjansky A, Licholai T. Evidence for distinctive and intrinsic defects in insulin action in polycystic ovary syndrome. Diabetes. 1992; 41: 1257-1266.
73. Holte J, Bergh T, Berne C, Wide L, Lithell H. Restored insulin sensitivity but persistently increased early insulin secretion after weight loss in obese women with polycystic ovary syndrome. J Clin Endocrinol Metab. 1995; 80: 2586-2593.
74. O'Meara NM, Blackman JD, Ehrmann DA, et al. Defects in β-cell function in functional ovarian hyperandrogenism. J Clin Endocrinol Metab. 1993; 76: 1241-1247. (Pubitemid 23155443)
75. Waterworth DM, Bennett ST, Gharani N, et al. Linkage and association of insulin gene VNTR regulatory polymorphism with polycystic ovary syndrome. Lancet. 1997; 349: 986-990. (Pubitemid 27149802)
76. Eaves IA, Bennett ST, Forster P, et al. Transmission ratio distortion at the INS-IGF2 VNTR. Nat Genet 1999; 22: 324-325. (Pubitemid 29369519)
77. Michelmore K, Ong K, Mason S, et al. Clinical features in women with polycystic ovaries: relationships to insulin sensitivity, insulin gene VNTR and birth weight. Clin Endocrinol. 2001; 55: 439-446. (Pubitemid 32955480)
78. Calvo RM, Telleria D, Sancho J, San Millan JL, Escobar-Morreale HF. Insulin gene variable number of tandem repeats regulatory polymorphism is not associated with hyperandrogenism in Spanish women. Fertil Steril. 2002; 77: 666-668. (Pubitemid 34275340)
79. Vankova M, Vrbikova J, Hill M, Cinek O, Bendlova B. Association of insulin gene VNTR polymorphism with polycystic ovary syndrome. An New York Acad Sci. 2002; 967: 558-565. (Pubitemid 34721947)
80. Goldfine ID. The insulin receptor: molecular biology and transmembrane signalling. Endocrine Rev. 1987; 8: 235-255.
81. Sorbara LR, Tang Z, Cama A, et al. Absence of insulin receptor gene mutations in three insulin-resistant women with the polycystic ovary syndrome. Metabolism. 1994; 43: 1568-1574. (Pubitemid 24382710)
82. Conway GS, Avey C, Rumsby G. The tyrosine kinase domain of the insulin receptor gene is normal in women with hyper-insulinaemia and polycystic ovary syndrome. Hum Reprod. 1994; 9: 1681-1683 (Pubitemid 24291083)
83. Talbot JA, Bicknell EJ, Rajkhowa M, Krook A, O'Rahilly S, Clayton RN. Molecular scanning of the insulin receptor gene in women with polycystic ovarian syndrome. J Clin Endocrinol Metab. 1996; 81: 1979-1983. (Pubitemid 26152495)
84. Urbanek M, Woodroffe A, Ewens KG, et al. Candidate gene region for polycystic ovary syndrome on chromosome 19p13.2. J Clin Endocrinol Metab. 2005; 90: 6623-6629. (Pubitemid 41759325)
85. Siegel S, Futterweit W, Davies TF, et al. A C/T single nucleotide polymorphism at the tyrosine kinase domain of the insulin receptor gene is associated with polycystic ovary syndrome. Fertil Steril. 2002; 78: 1240-1243. (Pubitemid 35469148)
86. Hubbard SR, Wei L, Ellis L, Hendrickson WA. Crystal structure of the tyrosine kinase domain of the human insulin receptor. Nature. 1994; 372: 746-754.
87. Orio F, Palomba S, Colao A. Cardiovascular risk in women with polycystic ovary syndrome. Fertil Steril. 2006; 86(Suppl 1): S20-21. (Pubitemid 43913766)
88. White MF. IRS proteins and the common path to diabetes. Am J Physiol Endocrinol Metab. 2002; 283: E413-E422.
89. Burks DJ, White MF. IRS proteins and beta-cell function. Diabetes. 2001; 50 (Suppl1): S140-S145.
90. Jellema A, Zeegers MPA, Feskens EJM, Dagnelie PC, Mensink RP. Gly972Arg variant in the insulin receptor substrate-1 gene and association with type 2 diabetes: a metaanalysis of 27 studies. Diabetologia. 2003; vol:990-995. (Pubitemid 36961324)
91. El Mkadem SA, Lautier C, Macari F, et al. Role of allelic variants Gly972Arg of IRS-1 and Gly1057Asp of IRS-2 in moderate- to-severe insulin resistance of women with polycystic ovary syndrome. Diabetes. 2001; 50: 2164-2168. (Pubitemid 33643687)
92. Ehrmann DA, Tang X, Yoshiuchi I, Cox NJ, Bell GI. Relationship of insulin receptor substrate-1 and -2 genotypes to pheno-typic features of polycystic ovary syndrome. J Clin Endocrinol Metab. 2002; 87: 4297-4300.
93. Villuendas G, Botella-Carretero JI, Roldan B, Sancho J, Escobar- Morreale HF, SanMillan JL. Polymorphisms in the insulin receptor substrate-1 (IRS-1) gene and the insulin receptor substrate-2 (IRS-2) gene influence glucose homeostasis and body mass index in women with polycystic ovary syndrome and non-hyperandrogenic controls. Hum Reprod. 2005; 20: 3184-3191. (Pubitemid 41662676)
94. Dilek S, Ertunc D, Tok EC, Erdal EM, Aktas A. Association of Gly972Arg variant of insulin receptor substrate-1 with metabolic features in women with polycystic ovary syndrome. Fertil Steril. 2005; 84: 407-412. (Pubitemid 41125262)
95. Ertunc D, Tok EC, Aktas A, Erdal EM, Dilek S. The importance of IRS-1 Gly972Arg polymorphism in evaluating the response tometformin treatment in polycystic ovary syndrome. Hum Reprod. 2005; 20: 1207-1212. (Pubitemid 40790243)
96. Sreenan SK, Zhou YP, Otani K, et al. Calpains play a role in insulin secretion and action. Diabetes. 2001; 50: 2013-2020. (Pubitemid 33643667)
97. Horikawa Y, Oda N, Cox NJ, et al. Genetic variation in the gene encoding calpain-10 is associated with type 2 diabetes mellitus. Nat Genet. 2000; 26: 163-175. (Pubitemid 30764497)
98. Ehrmann DA, Schwarz PEH, Hara M, et al. Relationship of calpain-10 genotype to phenotypic features of polycystic ovary syndrome. J Clin Endocrinol Metab. 2002; 87: 1669-1673. (Pubitemid 34615255)
99. Gonzalez A, Abril E, Roca A, et al. Comment: CAPN10 alleles are associated with polycystic ovary syndrome. J Clin Endocrinol Metab. 2002; 87: 3971-3976. (Pubitemid 34879556)
100. Gonzalez A, Abril E, Roca A, et al. Specific CAPN10 gene haplotypes influence the clinical profile of polycystic ovary patients. J Clin Endocrinol Metab. 2003; 88: 5529-5536. (Pubitemid 37452766)
101. Haddad L, Evans JC, Gharani N, et al. Variation within the type 2 diabetes susceptibility gene calpain-10 and polycystic ovary syndrome. J Clin Endocrinol Metab. 2002; 87: 2606-2610 (Pubitemid 34655321)
102. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab. 2004; 89: 2548-2556.
103. Oksanen L, Tiitinen A, Kaprio J, Koistinen HA, Karonen SL, Kontula K. No evidence for mutations of the leptin or leptin receptor genes in women with polycystic ovary syndrome. Mol Hum Reprod. 2000; 6: 873-876. (Pubitemid 30744820)
104. Hu FB, Doria A, Li T, et al. Genetic variation at the adiponectin locus and risk of type 2 diabetes in women. Diabetes. 2004; 53: 209-213. (Pubitemid 38044717)
105. Stumvoll M, Tschritter O, Fritsche A, et al. Association of the T-G polymorphism in adiponectin (Exon 2) with obesity and insulin sensitivity: interaction with family history of type 2 diabetes. Diabetes. 2002; 51: 37-41. (Pubitemid 34517977)
106. Menzaghi C, Ercolino T, Di Paola R, et al. A haplotype at the adiponectin locus is associated with obesity and other features of the insulin resistance syndrome. Diabetes. 2002; 51: 2306-2312. (Pubitemid 34729040)
107. San Millan JL, Corton M, Villuendas G, Sancho J, Peral B, Escobar-Morreale HF. Association of the polycystic ovary syndrome with genomic variants related to insulin resistance, type 2 diabetes mellitus, and obesity. J Clin Endocrinol Metab. 2004; 89: 2640-2646. (Pubitemid 38766343)
108. Panidis D, Kourtis A, Kukuvitis A, et al. Association of the T45G polymorphism in exon 2 of the adiponectin gene with polycystic ovary syndrome: role of Δ 4-androstenedione. Hum Reprod. 2004; 19: 1728-1733. (Pubitemid 39144613)
109. Xita N, Georgiou I, Chatzikyriakidou A, et al. Effect of adiponectin gene polymorphisms on circulating adiponectin and insulin resistance indexes in women with polycystic ovary syndrome. Clin Chem. 2005; 51: 416-423. (Pubitemid 40175813)
110. Escobar-Morreale HF, Villuendas G, Botella-Carretero JI, et al. Adiponectin and resistin in PCOS: a clinical, biochemical and molecular genetic study. Hum Reprod. 2006; 21: 22570-32265 (Pubitemid 44530598)
111. Hotamisligil GS, Peraldi P, Budavari A, Ellis R, White MF, Spiegelman BM. IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-α- and obesity-induced insulin resistance. Sci. 1996; 271: 665-668. (Pubitemid 26052915)
112. Escobar-Morreale HF, Calvo RM, Sancho J, San Millan JL. TNF-α and hyperandrogenism: a clinical, biochemical, and molecular genetic study. J Clin Endocrinol Metab. 2001; 86: 3761-3767. (Pubitemid 32755973)
113. Peral B, San Millan JL, Castello R, Moghetti P, Escobar- Morreale HF. Comment: the methionine 196 arginine polymorphism in exon 6 of the TNF receptor 2 gene (TNFRSF1B) is associated with the polycystic ovary syndrome and hyperandrogenism. J Clin Endocrinol Metab. 2002; 87: 3977-3983. (Pubitemid 34879557)
114. Villuendas G, San Millan JL, Sancho J, Escobar-Morreale HF. The -597 G → and -174 G → C polymorphisms in the promoter of the IL-6 gene are associated with hyperandrogenism. J Clin Endocrinol Metab. 2002; 87: 1134-1141. (Pubitemid 36121078)
115. Escobar-Morreale HF, Calvo RM, Villuendas G, Sancho J, San Millan JL. Association of polymorphisms in the interleukin 6 receptor complex with obesity and hyperandrogenism. Obes Res. 2003; 11: 987-996. (Pubitemid 41137511)
116. Yildiz BO, Haznedaroglu IC, Kirazli S, Bayraktar M. Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metab. 2002; 87: 3871-3875. (Pubitemid 34879542)
117. Legro RS. Polycystic ovary syndrome and cardiovascular disease: a premature association? Endocr Rev. 2003; 24: 302-312.
118. Diamanti-Kandarakis E, Palioniko G, Alexandraki K, Bergiele A, Koutsouba T, Bartzis M. The prevalence of 4G5G polymorphism of plasminogen activator ihibitor-1 (PAI-1) gene in polycystic ovarian syndrome and its association with plasma PAI-1 levels. Eur J Endocrinol. 2004; 150: 793-798. (Pubitemid 38961652)
119. Nayak S, Lee PA, Witchel SF. Variants of the type II 3β- hydroxysteroid dehydrogenase gene in children with premature pubic hair and hyperandrogenic adolescents. Mol Genet Metab. 1998; 64: 184-192. (Pubitemid 28453297)
120. Moghrabi N, Hughes IA, Dunaif A, Andersson S. Deleterious missense mutations and silent polymorphism in the human 17β-hydroxysteroid dehydrogenase 3 gene (HSD17B3). J Clin Endocrinol Metab. 1998; 83: 2855-2860. (Pubitemid 28493788)
121. Legro RS, Muhleman DR, Comings DE, Lobo RA, Kovacs BW. A dopamine 3 receptor genotype is associated with hyperandrogenic chronic anovulation and resistant to ovulation induction with clomiphene citrate in female Hispanics. Fertil Steril. 1995; 63: 779-784.
122. Kahsar-Miller M, Boots LR, Azziz R. Dopamine D3 receptor polymorphism is not associated with the polycystic ovary syndrome. Fertil Steril. 1999; 71: 436-438. (Pubitemid 29096635)
123. Zhao SP, Tang XM, Shao DH, Dai HY, Dai SZ. Association study between a polymorphism of aldosterone synthetase gene and the pathogenesis of polycystic ovary syndrome. Zhonghua Fu Chan Ke Za Zhi. 2003; 38: 94-97.
124. Rajkhowa M, Talbot JA, Jones PW, Clayton RN. Polymorphism of glycogen synthetase gene in polycystic ovary syndrome. Clin Endocrinol. 1996; 44: 85-90. (Pubitemid 26025689)
125. Urbanek M, Du Y, Silander K, et al. Variation in resistin gene promoter not associated with polycystic ovary syndrome. Diabetes. 2003; 52: 214-217. (Pubitemid 36042130)
126. Heinonen S, Korhonen S, Hippelainen M, Hiltunen M, Mannermaa A, Saarikoski S. Apolipoprotein E alleles in women with polycystic ovary syndrome. Fertil Steril. 2001; 75: 878-880. (Pubitemid 32401663)